Molecular dynamics simulation in virus research by Hirotaka Ode et al.
REVIEW ARTICLE
published: 19 July 2012
doi: 10.3389/fmicb.2012.00258
Molecular dynamics simulation in virus research
Hirotaka Ode1,2*, Masaaki Nakashima1,3, Shingo Kitamura1,3, Wataru Sugiura1,4 and Hironori Sato2
1 Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
2 Pathogen Genomics Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
3 Department of Biotechnology, Graduate School of Engineering, Nagoya University, Nagoya, Aichi, Japan
4 Department of AIDS Research, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan
Edited by:
Masaru Yokoyama, National Institute
of Infectious Diseases, Japan
Reviewed by:
Hiroyuki Toh, National Institute of
Advanced Industrial Science and
Technology, Japan
Yasuyuki Miyazaki, The University of
Tokushima Graduate School, Japan
*Correspondence:
Hirotaka Ode, Department of
Infectious Diseases and
Immunology, Clinical Research
Center, National Hospital
Organization Nagoya Medical
Center, 4-1-1 Sannomaru, Naka-ku,
Nagoya, Aichi, 460-0001, Japan.
e-mail: odehir@nih.go.jp
Virus replication in the host proceeds by chains of interactions between viral and
host proteins. The interactions are deeply influenced by host immune molecules and
anti-viral compounds, as well as by mutations in viral proteins. To understand how these
interactions proceed mechanically and how they are influenced by mutations, one needs
to know the structures and dynamics of the proteins. Molecular dynamics (MD) simulation
is a powerful computational method for delineating motions of proteins at an atomic-scale
via theoretical and empirical principles in physical chemistry. Recent advances in the
hardware and software for biomolecular simulation have rapidly improved the precision
and performance of this technique. Consequently, MD simulation is quickly extending the
range of applications in biology, helping to reveal unique features of protein structures that
would be hard to obtain by experimental methods alone. In this review, we summarize the
recent advances in MD simulations in the study of virus–host interactions and evolution,
and present future perspectives on this technique.
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INTRODUCTION
Proteins fluctuate spontaneously in solution (Ishima and Torchia,
2000). Accumulating evidence indicates that such fluctuations
play key roles in the specific functions of proteins, such as cat-
alytic reactions of enzymes (Nicholson et al., 1995; Lu et al.,
1998; Eisenmesser et al., 2005; Henzler-Wildman et al., 2007;
Abbondanzieri et al., 2008), interactions with other biomolecules
(Thorpe and Brooks, 2007), and biomolecular motors and pumps
(Astumian, 1997). Multiple experimental methods are available
to characterize the protein dynamics (Figure 1). However, it is
usually difficult to delineate motions of proteins at an atomic
scale.
MD SIMULATION IN BIOLOGY
OUTLINE
Molecular dynamics (MD) simulation is a computational method
to address the above issue (Figure 1) (Henzler-Wildman and
Kern, 2007; Dror et al., 2010). This technique enables us to calcu-
late movements of atoms in a molecular system, such as proteins
in water, by numerically solving Newton’s equations of motions
(Karplus and Petsko, 1990; Adcock and McCammon, 2006). In a
simple molecular system, all atoms and covalent bonds connect-
ing the atoms are assumed to be the charged spheres and springs,
respectively. Parameters of mathematical functions describing the
potential energy of a system, termed the “force field,” are set
to simulate the movements of atoms and molecules. Frequently
used force fields for proteins, such as the “AMBER” (Pearlman
et al., 1995; Case et al., 2005) and “CHARMM” (Brooks et al.,
2009) force fields, have the formulae of covalent bonds, angles,
dihedrals, van der Waals, and electrostatic potentials.
PERFORMANCE AND CONSISTENCYWITH EXPERIMENTAL DATA
Application of MD simulation in the field of protein chemistry
was first reported in 1977 (McCammon et al., 1977). Since then,
the performance of this technique have been quickly improved
quantitatively and qualitatively along with the rapid advances in
hardware and software on biomolecular simulation (Lindorff-
Larsen et al., 2012). The results of MD simulation are critically
influenced by the force fields (Lindorff-Larsen et al., 2012). The
qualities of parameters in the force fields, especially for dihedrals
and electrostatic potentials, have been improved quantitatively
and qualitatively over time by introducing improved approxi-
mation to the quantum ground-state potential energy surface.
Recently, eight different protein force fields were evaluated on
the basis of the consistency of simulations with the NMR data
(Lindorff-Larsen et al., 2012). The study demonstrates that the
most recent versions, while not perfect, provide results that are
highly consistent with the experimental data (Lindorff-Larsen
et al., 2012). In addition, explicit introduction of effects of the
solvation has contributed to the qualitative improvement for
the precision and performance of MD simulations (Adcock and
McCammon, 2006).
MD IN STRUCTURAL BIOLOGY
MD simulation currently allows us to investigate the structural
dynamics of proteins on timescales of nanoseconds to microsec-
onds, and will probably allow investigation to milliseconds in the
future (Figure 1) (Henzler-Wildman and Kern, 2007; Dror et al.,
2010). This technique is widely used in the field of structural
biology (Karplus and McCammon, 2002; Karplus and Kuriyan,
2005; Dodson et al., 2008). First, MD simulation is useful
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FIGURE 1 | Temporal resolution of various biophysical techniques. The timescales of some fundamental atom- or molecule-scale motions are shown
below. AFM, atomic force microscopy; FRET, fluorescence resonance energy transfer; IR, infrared radiation; NMR, nuclear magnetic resonance.
for refining the experimentally determined three-dimensional
(3-D) structures of proteins (Autore et al., 2010; Ozen et al.,
2011). Second, MD simulation is beneficial for constructing
previously undescribed 3-D structures of proteins in combina-
tion with homology modeling techniques (Marti-Renom et al.,
2000; Sanchez et al., 2000; Baker and Sali, 2001), when a reported
structure of a homolog is available. Third and most importantly,
MD simulation provides a unique tool to address the struc-
tural dynamics of proteins, i.e., the time evolution of conforma-
tions in solution, at timescales of nanoseconds to microseconds
(Henzler-Wildman and Kern, 2007; Dror et al., 2010). The struc-
tural snapshots obtained during MD simulation are helpful for
depicting the unique structural features of proteins (Karplus and
McCammon, 2002; Karplus and Kuriyan, 2005; Dodson et al.,
2008).
MD SIMULATION IN VIROLOGY
To date, MD simulations have been applied in a range of virus
researches, as shown in the following sections.
NEUTRALIZATION ESCAPE AND CELL TROPISM SWITCHING OF HIV-1
MEDIATED BY AN ELECTROSTATICMECHANISM
It is very important to clarify how viruses evade neutraliza-
tion antibodies in order to understand the viral life cycle and
evolution, and to develop vaccines. MD simulation is used to
address this issue as it pertains to human immunodeficiency virus
type 1 (HIV-1). The third variable (V3) loop of the HIV-1 enve-
lope gp120 protein constitutes the major antibody epitopes of
HIV-1 and the major determinants for the entry coreceptor use
of HIV-1. By analyzing the 40,000 structural snapshots obtained
from 10–30 ns of MD simulations of the identical gp120 outer
domain carrying a distinct V3 loop with net charge of +3 or
+7, Yokoyama and colleagues showed that the change in V3 net
charge alone is sufficient to induce global changes in fluctuation
and conformation of the loops involved in binding to CD4,
coreceptor, and neutralizing antibodies (Naganawa et al., 2008;
Yokoyama et al., 2012). Structural changes caused by a reduc-
tion in the V3 net charge via V3 mutations are tightly linked to
viral CCR5 coreceptor tropism (Naganawa et al., 2008), as well
as to a reduction in viral neutralization sensitivity to anti-V3
antibodies (Naganawa et al., 2008) and anti-CD4 binding site
monoclonal antibodies (Yokoyama et al., 2012). These findings
suggest a hitherto unrecognized mechanism, V3-mediated elec-
trostatic modulation of the structure and dynamics of the gp120
interaction surface, for adjusting the relative replication fitness
and evolution of HIV-1 (Yokoyama et al., 2012). In addition, they
partly explain a virological mystery, i.e., why HIV-1 variants using
CCR5, which carries a V3 loop with a lower level of positive net
charge, predominantly persist before the onset of AIDS.
MECHANISMS OF VIRAL ESCAPE FROM HOST DEFENSE SYSTEMS
Viruses also evade host defense systems other than neutraliza-
tion antibodies (Figure 2). MD simulation is used to clarify the
structural basis for viral escape from host defense systems by
mutations. Mutations at the 120th amino acid in the HIV-2 cap-
sid protein play a key role in evading tripartite motif-containing
protein 5α (TRIM5α), an anti-retroviral cellular protein induced
by interferon, both in vivo (Onyango et al., 2010) and in vitro
(Song et al., 2007). An MD simulation study has revealed that the
mutations could extensively influence the conformation and fluc-
tuation of the interaction surface of capsid proteins by altering the
probability of hydrogen bond formation between helices 4 and 5
(Miyamoto et al., 2011).
HIV-1Vpu antagonizes an antiviral cellular protein termed
tetherin, also known as BST-2/CD317/HM1.24, by interac-
tion with the transmembrane (TM) domain of tetherin and
subsequent degradation (Douglas et al., 2010; Kobayashi et al.,
2011). An MD simulation suggests that alignment of the four
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FIGURE 2 | Life cycle of HIV-1 and interactions between viral proteins and host immune molecules.
amino acid residues (I34, L37, L41, and T45) on the same helical
face in the human tetherin TM domain is crucial for the Vpu-
mediated antagonism against human tetherin (Kobayashi et al.,
2011). The interface structure of the tetherin TM for the antago-
nism was also predicted by the MD simulation of another group
(Zhou et al., 2012) and experimentally confirmed by an NMR
study (Skasko et al., 2012).
MD simulation is also used to study the mechanisms of func-
tional interactions between cytotoxic T lymphocyte (CTL) epi-
tope and major histocompatibility complex (MHC) molecules
(Reboul et al., 2012). An MD simulation study has revealed that
a 13-mer epitope peptide from Epstein-Barr virus has the low
structural flexibility in an MHC molecule that induces a CTL
response but exhibits high flexibility in another MHC molecule
that cannot induce a CTL response (Reboul et al., 2012). Thus,
structural flexibility of CTL epitope region seems to be critical for
the specific recognition by MHC molecules, and mutations that
alter the flexibility may influence CTL response. There are other
viral proteins and immune molecules involved in viral evasion
from host defense systems (Neil and Bieniasz, 2009; Malim and
Bieniasz, 2012). MD simulations should also be applicable for the
studies of these molecules.
STRUCTURE AND FUNCTION OF VIRAL ENZYMES
Viral enzymes are essential for viral replications and thus are
important targets for anti-viral drug development. MD simu-
lations are used to study the basis of the structural dynamics
that allow the viral enzyme and its drug to function properly.
Viral polymerase (Pol) is essential for viral genome replication
in the viral life cycle. The Pol is composed of the fingers, palm,
and thumb subdomains, which form a cavity for the substrate
binding, as in eukaryotic Pol (Joyce and Steitz, 1994; Lamers
et al., 2006; Cameron et al., 2009). MD simulations suggest that
the finger and thumb domains of HIV-1 reverse transcriptase
(RT) are especially mobile among the various regions of this
enzyme (Zhou et al., 2005; Kirmizialtin et al., 2012). Themobility
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is severely attenuated by binding of allosteric non-nucleotide
RT inhibitors (NNRTIs) (Zhou et al., 2005). Interestingly, a
large conformational change of RT subdomains during millisec-
ond timescale simulations can lock the correct nucleotide at
the active site but promotes release of a mismatched nucleotide
(Kirmizialtin et al., 2012). Furthermore, conformational dynam-
ics leading to opening and closing motions of the substrate
binding cleft are highly conserved among four RNA Pols in the
picornavirus family, despite the amino acid identity being as low
as 30–74% (Moustafa et al., 2011). These findings are consistent
with each other and strongly suggest that the structural dynamics
of viral Pol play a key role in the polymerization.
Viral protease (PR) plays a key role in viral propagation by cat-
alyzing cleavages of viral precursor proteins (Pettit et al., 1994,
2002; Steven et al., 2005). HIV-1 PR and other retroviral PRs have
unique regions termed the “flaps” outside the substrate bind-
ing clefts (Dunn et al., 2002). MD simulation studies suggest
that the PR flaps in HIV-1 are intrinsically mobile, undergo-
ing conversions between the “semiopen,” “open,” and “closed”
conformations (Hornak et al., 2006; Deng et al., 2011). This
movement is severely attenuated upon placement of the substrate
or PR inhibitor in the binding cleft (Karthik and Senapati, 2011),
suggesting that flapmovement plays a critical role in PR function.
MD simulations are also used to study the structural dynamics
of the substrates of viral PR. Peptides corresponding to cleavage
junctions of viral precursor proteins of HIV-1 are intrinsically
unstructured in aqueous solution (Datta et al., 2011; Ode et al.,
2011). However, the folding preference of the junction peptides
may be different among the junctions and related to the efficiency
of substrate binding and cleavage reaction by PR (Ode et al.,
2011). Furthermore, peptides at the capsid-p2 junction can adopt
a helical conformation when the polarity of the environment is
reduced (Datta et al., 2011). The MD simulation of PR and its
substrates will help to clarify how the viral precursor is processed
orderly during viral maturation.
DRUG-RESISTANCEMECHANISMS
Antiviral drug resistance is a major clinical problem for the treat-
ment of virus-infected individuals (Cortez and Maldarelli, 2011;
van der Vries et al., 2011). Viral resistance to antiviral drugs is
primarily caused by genetic mutations that eventually lead to a
reduction in the drug affinity of drug target viral proteins. MD
simulations are used to examine how viral mutations cause the
drug resistance at the atomic level.
A reduction in the binding affinity of the PR inhibitors to
HIV-1 PR can be caused by a reduction in hydrophobic interac-
tions (Kagan et al., 2005; Wittayanarakul et al., 2005; Sadiq et al.,
2007; Chen et al., 2010; Dirauf et al., 2010), reduction in elec-
trostatic interactions (Ode et al., 2005, 2006, 2007a; Chen et al.,
2010), changes in flexibility at the flap of the PR (Piana et al.,
2002; Perryman et al., 2004; Chang et al., 2006; Foulkes-Murzycki
et al., 2007), and changes in the shape of the inhibitor-binding
pocket (Ode et al., 2005, 2006, 2007b). Reduction in binding
affinity of the nucleotide/nucleoside RT inhibitors (NRTIs) to
HIV-1 RT can be caused by a distinct conformational prefer-
ence of NRTIs in the substrate/NRTI-binding site compared to
normal substrates (Carvalho et al., 2006) or enhancement of
ATP-mediated excision of misincorporated nucleotide analogs
via increased accessibility of ATP to the terminus of extending
DNA (White et al., 2004; Carvalho et al., 2007). Reduction in the
binding affinity of the NNRTIs to HIV-1 RT can be attained by
occlusion of the NNRTI-entry pathway (Rodriguez-Barrios and
Gago, 2004; Rodriguez-Barrios et al., 2005) or restoration of the
proper flexibility of the RT even with NNRTIs (Zhou et al., 2005).
A change in volume of the binding site of influenza virus (IFV)
M2 channel blockers has been shown to reduce the blockers’ bind-
ing affinity (Gu et al., 2011; Leonov et al., 2011; Wang et al.,
2011). Disruption of the proper guidance of IFV neuraminidase
(NA) inhibitors into their binding pocket is proposed as a pos-
sible mechanism for the reduction in the binding affinity of the
inhibitors (Le et al., 2010; Kasson, 2012). MD simulations are also
used to study how the genetic differences of HIV variants around
the world can influence the efficacy of antiviral inhibitors (Batista
et al., 2006; Ode et al., 2007a; Matsuyama et al., 2010; Soares
et al., 2010; Kar and Knecht, 2012). Thus, MD simulation will be
valuable to assist in the study of drug efficacy when genetic infor-
mation on the drug target proteins is available (Shenderovich
et al., 2003; Stoica et al., 2008; Sadiq et al., 2010; Wright and
Coveney, 2011).
ANTIVIRAL DRUG DISCOVERY AND DEVELOPMENT
MD simulations are used to assist in the discovery and develop-
ment of antiviral drugs (Durrant andMcCammon, 2011; Borhani
and Shaw, 2012). MD simulations allow sampling snapshots of
fluctuated protein structures, which include their short-lived con-
formations as well as stable conformations. This is beneficial for
searching conformations of a protein on ligand-binding, since
ligand-binding can stabilize conformation of a protein that is not
the most stable at ligand-free state (Tobi and Bahar, 2005; Xu
et al., 2008). Thus, the MD simulations are used to improve the
enrichment performance of molecular docking during in silico
drug screening by taking accounts of multiple docking poses
(Okimoto et al., 2009). The method is also applied for identify-
ing concealed drug-binding sites, which are apparently masked
and not evident from the X-ray crystal structures, by considering
the structural flexibility of proteins. For example, MD simulations
have been used to find a trench adjacent to the active site of HIV-1
integrase (Schames et al., 2004). A site-directed mutagenesis study
provided evidence that the trench indeed plays key roles in ligand-
binding (Lee and Robinson, 2006). These findings have been used
to design HIV-1 integrase inhibitors with potent antiviral effects
(Durrant and McCammon, 2011).
Likewise, MD simulations are used to assist in the develop-
ment of antiviral drugs against IFV. Using this method, a universal
cavity adjacent to the binding site of natural substrate has been
reported with NA proteins of human 2009 pandemic H1N1, avian
H5N1, and human H2N2 strains (Amaro et al., 2011). MD sim-
ulations were also used to construct a 3-D structure model of
CCR5, a major coreceptor of HIV-1 (Maeda et al., 2008; Da and
Wu, 2011).
VIRION STRUCTURE
It is essential to clarify the structure of virions in order to
understand the mechanisms of viral infection and assembly.
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FIGURE 3 | Molecular scales of viral proteins and capsid particles.
The structures of HIV-1 PR (PDB code: 1HHP), HIV-1 RT (PDB code: 1RTD),
STMV (PDB code: 1A34), and poliovirus capsid particle (PDB code: 1HXS),
which are deposited in the Protein Data Bank (PDB)
(http://www.rcsb.org/pdb/home/home.do) or the VIPERdb
(http://viperdb.scripps.edu/), are shown in surface representation.
MD simulation is used to address this issue. Using a super com-
puter, Freddolino et al. performed 50-nanosecond-timescale MD
simulations of the symmetric structure of a complete satellite
tobacco mosaic virus (STMV) particle containing about 1 million
atoms (Arkhipov et al., 2006) (Figure 3). Thus, far, this is one of
the largest systems among theMD simulations reported in all bio-
logical fields. Notably, the virion with viral RNAwas stable during
the simulations, whereas the one without the RNA was unsta-
ble, suggesting that viral RNA plays a key role in stabilizing the
STMV virion (Arkhipov et al., 2006). The study is consistent with
the experimental data (Day et al., 2001) and therefore provides
a set of rationale conditions for performing the MD simulation
of virion. Likewise, Larsson et al. reported about 1-microsecond-
timescale MD simulations of the satellite tobacco necrosis virus
(STNV) (Larsson et al., 2012). Their study reproduced the bio-
chemical phenomenon of the STNV virion in solution (Unge
et al., 1986), i.e., the swelling of capsid upon Ca2+ removal by
EDTA treatment. These findings will provide a structural basis for
identifying the key regulators of assembly and infections and for
illustrating how they function mechanically. Although MD simu-
lation of virions composed of very large numbers of atoms is still
difficult in most cases, progress in the hardware and software for
the simulation, together with the accumulation of biological and
physicochemical information on virions, will help us to overcome
these limitations in the MD simulation of virions.
PERSPECTIVE
Since the processing speed of computers is still doubling approxi-
mately every two years according to Moore’s law, MD studies will
be extended to simulations of larger and more complex system at
longer timescales. This will then lead to a better understanding
of the structures and dynamics of macromolecules involved in
virus–host interactions.
COARSE-GRAINED (CG) MD SIMULATIONS
MD simulations of macromolecules consisting of large molecular
systems, such as oligomeric proteins, macromolecular complexes,
and membrane proteins in a lipid bilayer, and virions are desired
to better understand viruses. However, such simulations require
unrealistically long analytical times and high-performance com-
puters at present, and thereby are still limited mostly to the
small molecules (Henzler-Wildman and Kern, 2007; Dror et al.,
2010). To cope with this issue and to improve the practicabil-
ity of long timescale MD simulation, a “coarse-grained (CG)
MD” simulation has been developed (Merchant and Madura,
2011; Takada, 2012). The CG-MD simulation employs “pseudo-
atoms” that consist of several atoms in a group and calculates the
movement of these “pseudo-atoms” rather than the movement
of “individual atoms,” thereby greatly reducing the calculation
time (Merchant and Madura, 2011; Takada, 2012). CG-MD sim-
ulations have been used to study helicases of hepatitis C virus
(HCV) and simian virus 40 and have successfully reproduced
enzyme motions, such as “ratcheting inchworm translocation”
and “spring-loaded DNA unwinding” (Flechsig and Mikhailov,
2010; Yoshimoto et al., 2010). Briefly, the ratcheting inchworm
translocation is the unidirectional motion of the HCV NS3 heli-
case during translocation that occurs by the step size of one base
per ATP hydrolysis cycle (Gu and Rice, 2010). Meanwhile, the
spring-loaded DNA unwinding is the discrete steps of unwind-
ing of DNA by the HCV NS3 helicase that occurs periodically via
a burst of 3-bp unwinding during NS3 translocation consuming
ATPs (Myong et al., 2007).
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CG-MD has also been applied to the study of the structural
characteristics and stabilities of the capsid particle and virion
(Figure 3). Such studies have been used to investigate small
plant viruses (∼28 nanometer in diameter), such as the three
satellite plant viruses STMV, STNV, and the satellite panicum
mosaic virus (SPMV), as well as the brome mosaic virus (BMV)
(Arkhipov et al., 2006, 2009), and more complex capsids such
as poliovirus (Arkhipov et al., 2006, 2009), asymmetric, conical-
shaped HIV-1 capsid particles (Krishna et al., 2010), and the
immature HIV-1 virion (Ayton and Voth, 2010). These studies
have predicted various molecular interactions that can be tested
experimentally. Thus, CG-MD may play a pivotal role in the
MD study of micrometer-sized systems at millisecond timescale
(Merchant and Madura, 2011; Takada, 2012) and therefore may
uncover novel characteristics of the interactions in virus–host
relationships.
INTRINSICALLY DISORDERED PROTEINS
Some eukaryotic proteins have no stable 3-D structure under
physiological conditions (Dunker et al., 2002, 2008; Dyson and
Wright, 2005). These proteins are referred to as intrinsically
disordered, natively unfolded, or intrinsically unstructured pro-
teins. They undergo structural transition from a disordered to
an ordered state upon binding to target molecules such as
proteins, DNA, and small molecules (Dunker et al., 2005; Sandhu
and Dash, 2007). They are often related to the “hub proteins”
that have many binding partners and control important bio-
logical processes (Iakoucheva et al., 2002; Haynes et al., 2006;
Sandhu, 2009). Interestingly, viral proteins or portions of viral
proteins are often intrinsically disordered. These include genome-
linked protein VPg protein of plant viruses (Grzela et al., 2008;
Rantalainen et al., 2008; Jiang and Laliberte, 2011; Rantalainen
et al., 2011), HIV-1 Tat (Shojania and O’Neil, 2010), and Vif
proteins (Reingewertz et al., 2010), and paramyxovirus nucle-
oproteins and phosphoproteins (Habchi and Longhi, 2012). It
has been proposed that the disordered structure is beneficial
for viruses to gain multiple functions in the viral life cycle
with limited genome size (Rantalainen et al., 2011; Habchi and
Longhi, 2012; Xue et al., 2012). Clarifying the folding land-
scape of viral proteins by standard MD and CG-MD simula-
tions may help in understanding the structural principles by
which viral proteins execute multiple functions in the viral life
cycle.
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